Trastuzumab - Mechanism of action and use [12]

New England Journal of Medicine

Volumn 357, Issue 16, 2007, Pages 1664-1666

  Karamouzis, Michalis V ^a   Konstantinopoulos, Panagiotis A ^b   Papavassiliou, Athanasios G ^c  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; MITOGEN ACTIVATED PROTEIN KINASE; NEU DIFFERENTIATION FACTOR; TRASTUZUMAB; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; EPIDERMAL GROWTH FACTOR RECEPTOR; IMMUNOGLOBULIN G1; INFLIXIMAB; NAVELBINE; PACLITAXEL; RITUXIMAB;

BREAST CANCER; CANCER CHEMOTHERAPY; CARCINOGENESIS; DRUG MECHANISM; DRUG USE; HUMAN; LETTER; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BINDING; BREAST TUMOR; DRUG EFFECT; FEMALE; FETUS; IMMUNOLOGY; NOTE; PREGNANCY; METABOLISM; ADJUVANT THERAPY; DRUG TRANSPORT; HYDRAMNIOS; LOW BIRTH WEIGHT; NEONATAL RESPIRATORY DISTRESS SYNDROME; PLACENTA; TERATOGENICITY;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; FETUS; HUMANS; PREGNANCY; RECEPTOR, ERBB-2; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 35348980687     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc072213     Document Type: Letter

References (5)

1. Hudis CA. Trastuzumab - mechanism of action and use in clinical practice. N Engl J Med 2007;357:39-51.
2. Karamouzis MV, Grandis JR, Argiris A. Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas. JAMA 2007;298:70-82.
3. Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 2006;7:505-16.
4. de Alava E, Ocaña A, Abad M, et al. Neuregulin expression modulates clinical response to trastuzumab in patients with metastatic breast cancer. J Clin Oncol 2007;25:2656-63.
5. Menendez JA, Mehmi I, Lupu R. Trastuzumab in combination with heregulin-activated Her-2 (erbB-2) triggers a receptor-enhanced chemosensitivity effect in the absence of Her-2 overexpression. J Clin Oncol 2006;24:3735-46.